Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by ronrydellon Aug 18, 2015 11:17am
130 Views
Post# 24027722

RE:RVX vs. ESPR leadership matters...

RE:RVX vs. ESPR leadership matters...Back in 2007 I flew from Mpls to Calgary to attend the annual AGM to meet the management and get a idea of who was running RVX and getting acquainted. I also pulled off a breakfast meeting Roger Newton at the Hyatt, who had just joined the board and was considered a real coup for RVX. 

My objective, as a non science person was to get his feel of the future ...his response.."we'll learn a lot about what the science can do as we proceed to the IND and subsequent trials. Several months later he left the board and there was NO DISCUSSION subsequent to that about why. Next thing I heard he was back with Esperion, a company he had previously sold to,Pfizer....Pfizer sold again for much less then they paid...and now they are back in spades.


Did Roger Newton pick,the brains of Dr Johannason....learn our secret sauce and use it for Esperion? Sure would like to know why he joined our board, left shortly, and is where he is now. Although we use a pill and they don't why are they so well regarded in comparison to RVX? 
Although they haven't had the setbacks RVX has had...either they are way overvalued or we are way undervalued. Love to,get some answers.....maybe someone can ask during the Q@A at the AGM.
Bullboard Posts